Verona Pharma Plc News - VRNA

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024

One oral presentation and three posters support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual...

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

OhtuvayreTM (ensifentrine) now available; patient shipments started Strong balance sheet supports...

Form 4 - Statement of changes in beneficial ownership of securities

Verona Pharma to Present at 44th Annual Canaccord Growth Conference

LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”...

Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)

Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients First...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

PDUFA Target Action Date for Ensifentrine of June 26, 2024 Finalizing commercial launch preparations Strong...

MegaPirate61 1 week ago

According to a msg board post the cfo said that their quarterly expenses were 50 million and sales were now break even and will soon be exceeding that.

👍️ 2

powerwalker 1 week ago

While it might not be making a presentation, Verona execs are at the JPM Healthcare Conference, partaking in meetings with future impact.

👍️0

MegaPirate61 2 weeks ago

Posted a typo before the released shares that were already on the shelf total was 2.5 million shares not 12.5 mil

Do you ascribe this improvement to ohtuvayre Roger? Congratulations!

👍️ 1

Roger1 2 weeks ago

Good news. I've been able to cut my Prednisone in half and hopefully eliminate it soon. Have found I can stretch my nebulizer treatments to Q6-7 from Q4. Will be interesting to see how much more improvement I can get b4 allergy season in Mar/April.

👍️ 3

powerwalker 2 weeks ago

Roger, what is going on with you and your ohtuvayre experience?

We would like to hear about it.

👍️ 2

MegaPirate61 2 weeks ago

Well they went and announced unofficial earnings on their own today. Also says they sold 12.5 million shares at an avg of 39.50 of so through Jeffries. Must have something else to announce at jpm?

👍️ 1

powerwalker 2 weeks ago

Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights

https://finance.yahoo.com/news/verona-pharma-reports-strong-ohtuvayre-110000636.html

Sounds positive and noted the "J-code" that MegaPirate had emphasized. 👍️❤️

👍️ 1

powerwalker 2 weeks ago

Thank you, MegaPirate, for your reply.

👍️ 1

MegaPirate61 2 weeks ago

I'm not Hoskuld but the company said in q n a session last earnings call that they would announce unaudited q4 2024 sales at jpm around Jan 12 to 14 if I remember right. We will all need to be patient here. A launch doesn't really start until the second quarter of having a j code which is just now active. We will have a better indication in a year of the early results.

👍️0

powerwalker 3 weeks ago

Hoskuld, do you think Verona will be invited to JP Morgan Healthcare Conference next week?

👍️ 1

Hoskuld 4 weeks ago

That is so great Roger! How has ohtuvayre helped you? Easier to breathe? Less phlegm? Would you be willing to share your experience?

👍️ 2

powerwalker 1 month ago

Best of luck, Roger … it is time for a Christmas present for you and your elbow Virginians.

Merry Christmas and a prosperous 2025.
powerwalker

👍️0

Roger1 1 month ago

I can tell you the drug works for me. Acaria Pharma, specialty pharmacy filling rx's has thrown a wrench in the works by requiring Virginia patients to have additional Rx from the physician greatly increasing the time needed to fill. Ohtovayre patient portal reps are unaware. I've told 2 of them about it and emailed company but have not received any response. That was several weeks ago. I know my pulmonologist has prescribed it for several patients but I believe I may be the first to actually receive it.
,

👍️ 3

powerwalker 1 month ago

GIDDY-UP, VERONA, and all you hedge managers and investment bankers hitch yourselves to this rocket! It is ready to take-off!

👍️ 1

powerwalker 2 months ago

Let's go you, Investment advisors and hedge fund managers, get your valuation models going full tilt this weekend to calculate how quickly Verona can get to $100 ... and start buying!

👍️0

powerwalker 2 months ago

Hopefully, Verona will break the $40 ceiling and stay above it. Its performance deserves it.

👍️ 1

Hoskuld 2 months ago

PW another claim by management is that this is the best pulmonary launch ever (by far.)

👍️ 2

powerwalker 2 months ago

Thank you, Hoskuld. I'll listen to one of the two tomorrow.

👍️0

Hoskuld 2 months ago

I thought it was excellent PW: uptake is strong and docs are prescribing earlier in the disease cycle than anticipated which underscores the hunger for a differentiated therapy. Feedback from docs is good. Based on what he said, I expect the company will be cash flow positive by April.

🎯 1 👍️ 2

powerwalker 2 months ago

Any word on today's presentation?

👍️0

Roger1 2 months ago

Yes. Still waiting. Seems to be quite a process with Acaria pharmacy, Medicare, coinsurance. No idea where the process is at. I do know dr.s office has done all that's been asked. They are just as interested in any improvement as I am. Have a feeling I'm the guinea pig for this practice. <S>. I wonder if pharmacy is overwhelmed or is there some other reason. I'll let you know if I hear anything. Have a great day.

👍️ 3

powerwalker 2 months ago

Good morning, Roger:

Did the doctor's office get things right, so you are now on Ohtuvayre?

If so, let us know how it is helping.

👍️0

powerwalker 2 months ago

Upcoming next week:

Verona Pharma Announces December 2024 Investor Conference Participation
Share

LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in December 2024:

Piper Sandler 36th Annual Healthcare Conference
Date: Tuesday, December 3, 2024
Time: 12:00 p.m. ET / 5:00 p.m. GMT
Location: New York, NY

7th Annual Evercore HealthCONx Conference
Date: Wednesday, December 4, 2024
Time: 3:00 p.m. ET / 8:00 p.m. GMT
Location: Miami, FL

A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com.

https://www.veronapharma.com/news/verona-pharma-announces-december-2024-investor-conference-participation/

👍️ 1

MegaPirate61 2 months ago

Probably a moot point. If it's a 200 billion dollar asset over time the most big pharma will pay is 20b. And they will take it sooner rather than later. Maybe within the next 2 yrs.

👍️0

Hoskuld 2 months ago

Pricing is the US is pretty sweet - ROW not so much. If bicyclical then the motion will be elliptical.

👍️0

powerwalker 2 months ago

Does anyone have thoughts on yesterday's presentation? I read the slides and come away with the impression that Verona can serve 50% of the market with the focus on 80% of the HCPs intent to Prescribe Ohtuvayre.

With $1.1 billion in sales for each !% or 86K patients, those are BIG numbers down the road as Mega and Hoskuld shared earlier this week.

👍️ 1

MegaPirate61 2 months ago

Just search fintel Duquesne position of 680k shares you can validate this on multiple sites. Use ai in your searches lol

👍️ 1

powerwalker 2 months ago

Mega, article is behind a pay-wall for CNBC, so can't see it.

I think he will buy more ... sooner, rather than later.

👍️0

Roger1 2 months ago

It is in process. Mixup at doctors office. Verona and Acaria have been very supportive and helpful. Should be straightened out today.

👍️ 1

powerwalker 2 months ago

Roger, it appears that folks there liked what they heard as well as Druckenmiller's $20 million purchase would have encourage others to buy now. [I did not find anything, either. Possibly, later today it will be available.]

BTW, how is your situation? Have you received it?

👍️0

Roger1 2 months ago

I thought the presentation was to be webcast and found on the investor tab. I didn't find it this morning at 0630. Anyone else?

👍️0

powerwalker 2 months ago

Verona Pharma Announces December 2024 Investor Conference Participation

https://www.veronapharma.com/news/verona-pharma-announces-december-2024-investor-conference-participation/

Not the PR I was expecting for this morning ... hoping for data being shown today at Jefferies conference.

👍️0

powerwalker 2 months ago

Mega, great find. He is a top-notch investor.

👍️0

MegaPirate61 2 months ago

This guy Druckenmiller bought $20 mil worth vrna last month. https://www.cnbc.com/2024/11/18/druckenmiller-bought-regional-banks-but-a-healthcare-pick-is-his-biggest-bet.html

It's listed in a fund he manages. Duquesne.

👍️ 1

powerwalker 2 months ago

PR in morning before NYSE opens?

👍️0

MegaPirate61 2 months ago

Especially if soc in asthma and label expansion seasonal allergies... then it's worth is really high for that spring pollen pop. If international then it will be a bicyclical which would smooth the revenue curve. Lots of if statements of course.

👍️0

Hoskuld 2 months ago

Right - if SOC then this blows up in a good way.

👍️0

powerwalker 2 months ago

On November 19th, possibly updates on scripts//sales ...

Verona Pharma to Present at Jefferies London Healthcare Conference

https://finance.yahoo.com/news/verona-pharma-present-jefferies-london-070000088.html

👍️0

powerwalker 2 months ago

Hoskuld, any thing new on the scripts? Tough day yesterday.

👍️0

MegaPirate61 2 months ago

I'm seeing a lot of soc references in the commentary from the analysts and physicians networks. If that happens in asthma and copd it's 20 billion per month. Obviously that's a long shot but it's possible in 10 yrs. That's the scary thing.

👍️0

Hoskuld 2 months ago

LOL I like your sign off! I don't think most COPD patients will switch to ohtuvayre but will just add Oh (steroids are pretty cheap.) Add 250,000 bronchiectasis patients to probably 1.5m COPD patients and those add up to some immense numbers. Maybe I lack imagination, but I don't think $100b is in the cards - maybe $20b if every single thing goes well.

👍️ 1

MegaPirate61 2 months ago

New valuation of vrna at 218 per share per takeover advocate specialist Caligan.

https://www.cnbc.com/2024/11/09/caligan-takes-a-stake-in-verona-pharma-sees-opportunity-to-generate-more-value.html

I personally feel this estimate is way low. If a big part 4 million copd patients on steroids are switched over to ohtuvayre as fda is pushing, plus other combos in a progressive disease scenario (meaning eventually all copd patients will need something else to supplement their therapy) you're looking at 3300 per 3 month supply or 13 billion per quarter. Double that for the 1 million fibrosis patients plus asthmatic patients once approved, and that's 100 bil per yr + without international or other label expansion. Fairly safe to say it's a 250 billion dollar asset in 10 yrs all imo.

I'd put fair value at 2000 per share minimum. But what do I know I'm just a pirate. Ohtuvayrrrg!

👍️ 1

Hoskuld 3 months ago

And scripts are trending up in a big way - recently they have been doubling every 4 weeks.

👍️ 2

MegaPirate61 3 months ago

Insider purchases that appear to be about 200 grand worth, possible exercises of options but marked as acquired nov 6

👍️ 1

powerwalker 3 months ago

Why the pop over the last 90 minutes or so?

👍️0

Hoskuld 3 months ago

Hi PW! Scripts will just tell us the trend - which is strong right now - but cannot give us the absolute #s...which are about 2.5x-3x the IMS script data. I think the company would consider a buyout at the right price - IMO $100 right now would be OK based on the trend and the upside is huge from there.

👍️ 2

powerwalker 3 months ago

Thank you for your reply.

As to 1), will we learn of those higher revenues directly from Verona or indirectly via the weekly script info?

For 2), are the company's actions geared towards a take-out soon or later when more revenue sources are likely? or, will Glaxo and AZ jump the gun and go after Verona now that revenue is coming in strong for a sensational product?

Once again, thank you, Hoskuld.

👍️0

Hoskuld 3 months ago

I think there are 2 catalysts:

1. The continuous catalyst of higher and higher revenues and

2. Acquisition by Glaxo or AstraZeneca etc.

It will take a while for Bronchiectasis trial results but those will help, too.

👍️0

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Verona Pharma Plc (VRNA)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

VRNA News

Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Form 4 - Statement of changes in beneficial ownership of securities

Verona Pharma to Present at 44th Annual Canaccord Growth Conference

Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Form 8-K - Current report

Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

VRNA Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Verona Pharma Plc (VRNA) News

Verona Pharma Plc (VRNA)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

VRNA News

Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Form 4 - Statement of changes in beneficial ownership of securities

Verona Pharma to Present at 44th Annual Canaccord Growth Conference

Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Form 8-K - Current report

Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

VRNA Discussion

Your Recent History

Go Ad-Free